The triptan drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Triptan drug is used in the treatment of migraine. This drug is approved by the Food and Drug Administration of the United States. Migraine episodes that occur with aura (a medical condition in which there is a subjective sensation of voices and lights when a neurological disorder occurs) are treated with triptan drug. Several forms of this drug are available in different dosages such as sumatriptan. This drug is prescribed for the treatment of cluster headaches. Another form of triptan drug is almotriptan which is given to adolescents in case of migraine.
A full report of Global Triptan Drug Market is available at:https://orionmarketreports.com/global-triptan-drug-market/109572/
Zolmitriptan is a type of triptan which is approved by the Food and Drug Administration of the United States to be used in spray form. These are nasal sprays for children above 12 years. Frovatriptan, naratriptan, and oral zolmitriptan are some other types of triptan drugs that are prescribed in case of menstrual migraine. Migraine is a type of headache that can last up to 72 hours. Extreme cases of migraine episodes can result in vomiting with nausea. This affects the patients concretely as they are not in their senses. Along with medications, patients are given information about balanced meals and a healthy lifestyle. Pharmacologic and non-pharmacologic therapies are available for the treatment of migraine. In case of reducing the frequency of migraine attacks, Prophylactic therapy is mostly advised to patients. In case of a severe migraine attack, patients are advised abortive therapy. Prescription of triptans in migraine comes under abortive migraine therapy.
Triptan drugs act on migraine by binding themselves with serotonin receptors. Serotonin receptor (5-HT1B) when bound with a triptan, it leads to vasoconstriction of cranial arteries. These arteries dilate when a migraine episode occurs. The binding of serotonin receptor (5-HT1B) with triptan leads to reducevasoactive neuropeptides release by preventing the activation of trigeminal nerves. This in turn blocks the flow of pain signals to the brain. As per the World Health Organization, the prevalence rate of migraine episodes is 10% globally. Around the world, in a proportion of one million people, 3000 migraine attacks occur every day.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Application
- By End-User
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape-Teva Pharmaceutical Industries Ltd., AbbVie Inc, AstraZeneca PLC, Pfizer Inc.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Triptan DrugMarket Report by Segment
By Application
- Migraine
- Others
By End-User
- Hospital
- Clinic
- Others
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
